grade
pharmaceutical primary standard
API family
acetohydroxamic acid
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
CC(NO)=O
InChI
1S/C2H5NO2/c1-2(4)3-5/h5H,1H3,(H,3,4)
InChI key
RRUDCFGSUDOHDG-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Acetohydroxamic acid USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Acetohydroxamic Acid Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under 乙酰氧肟酸
signalword
Danger
hcodes
Hazard Classifications
Repr. 1B
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
flash_point_f
Not applicable
flash_point_c
Not applicable
Duminda N Wijeysundera et al.
Journal of the American College of Cardiology, 64(22), 2406-2425 (2014-08-06)
To review the literature systematically to determine whether initiation of beta blockade within 45 days prior to noncardiac surgery reduces 30-day cardiovascular morbidity and mortality rates. PubMed (up to April 2013), Embase (up to April 2013), Cochrane Central Register of
Rajesh V Swaminathan et al.
Journal of the American College of Cardiology, 65(12), 1161-1171 (2015-03-31)
There has been a decline in hospital length of stay (LOS) after primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI). The objective of this study was to examine whether shorter LOS is safe for older patients undergoing
Duminda N Wijeysundera et al.
Circulation, 130(24), 2246-2264 (2014-08-03)
To review the literature systematically to determine whether initiation of beta blockade within 45 days prior to noncardiac surgery reduces 30-day cardiovascular morbidity and mortality rates. PubMed (up to April 2013), Embase (up to April 2013), Cochrane Central Register of
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 1006506-200MG | 04061833858899 |